Company profile
Palisade Bio, Inc.
NASDAQ: PALI · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
71BFH 72DQ 72GM —SS 60
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$500.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$16.8M
Employees
14
as of 2026-08-12
Market cap
$371.5M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$16.8M-$16.8M2025
Operating income-$18.1M-$18.1M2025
Total assets$134.3M$134.3M2025
Liabilities$5.0M$5.0M2025
Equity$129.4M$129.4M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY18
FY19
FY20
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Palisade Bio, Inc.’s revenue?
Palisade Bio, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Larimar Therapeutics, Inc.38DCompass Therapeutics, Inc.50DRocket Pharmaceuticals, Inc.53DSAB Biotherapeutics, Inc.52DInhibikase Therapeutics, Inc.43DZentalis Pharmaceuticals, Inc.40DNeighbors
San Diego →Key facts
CEOJ. D. Finley
SectorHealthcare
IndustryBiotechnology
HeadquartersCarlsbad, CA
ExchangeNASDAQ: PALI
Employees14
IPO date2007-03-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.